Related references
Note: Only part of the references are listed.Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Laura M. Spring et al.
CLINICAL CANCER RESEARCH (2020)
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic
Mitch Dowsett et al.
NPJ BREAST CANCER (2020)
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
Hiroji Iwata et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Real-world data: towards achieving the achievable in cancer care
Christopher M. Booth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making
Vaibhav B. Katkade et al.
JOURNAL OF MULTIDISCIPLINARY HEALTHCARE (2018)
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Breast Cancer-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
Armando E. Giuliano et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry
N. Niikura et al.
ANNALS OF ONCOLOGY (2016)
Real-World Evidence - What Is It and What Can It Tell Us?
Rachel E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review
Tomas Reinert et al.
REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA (2016)
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy
A. Sheri et al.
ANNALS OF ONCOLOGY (2015)
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
C. Palmieri et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Optimum duration of neoadjuvant letrozole to permit breast conserving surgery
Robert Carpenter et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
Duveken B. Y. Fontein et al.
EUROPEAN JOURNAL OF CANCER (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
E. Alba et al.
ANNALS OF ONCOLOGY (2012)
Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2012)
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
Rodrigo Goncalves et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
Y. H. Chia et al.
BRITISH JOURNAL OF CANCER (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Increase in response rate by prolonged treatment with neoadjuvant letrozole
J. Michael Dixon et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer:: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
Ute E. Krainick-Strobel et al.
BMC CANCER (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
Vladimir F. Semiglazov et al.
CANCER (2007)
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer - The Pre-Operative Arimidex Compared to Tamoxilen (PROAC7) trial
L Cataliotti et al.
CANCER (2006)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists
M Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
